Abstract
Lingua originale | English |
---|---|
pagine (da-a) | 100-103 |
Numero di pagine | 4 |
Rivista | International Journal of Urology |
Volume | 2 |
Stato di pubblicazione | Published - 1995 |
Cita questo
Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study. / Pavone, C.; Pavone-Macaluso, M.
In: International Journal of Urology, Vol. 2, 1995, pag. 100-103.Risultato della ricerca: Article
}
TY - JOUR
T1 - Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?--a phase II study
AU - Pavone, C.; Pavone-Macaluso, M.
AU - Serretta, Vincenzo
AU - Piazza, Bruna
PY - 1995
Y1 - 1995
N2 - Clinical use of recombinant tumor necrosis factor-alpha is strongly limited by its severe toxicity, mainly cardiovascular, when systemically administered. Recent studies suggest that topical (intrapleural, intraperitoneal, intratumoral) administration is free of significant toxicity. Human recombinant tumor necrosis factor-alpha was administered intravesically, at a dose of 500 mg dissolved in 30 ml of phosphate buffer (pH 7.6-7.8) plus 0.25% human albumin, weekly for two months to 18 patients with papillary transitional cell carcinoma of the bladder. Of the 15 evaluable patients, four (26%) achieved a complete response. Systemic and local tolerability were excellent.
AB - Clinical use of recombinant tumor necrosis factor-alpha is strongly limited by its severe toxicity, mainly cardiovascular, when systemically administered. Recent studies suggest that topical (intrapleural, intraperitoneal, intratumoral) administration is free of significant toxicity. Human recombinant tumor necrosis factor-alpha was administered intravesically, at a dose of 500 mg dissolved in 30 ml of phosphate buffer (pH 7.6-7.8) plus 0.25% human albumin, weekly for two months to 18 patients with papillary transitional cell carcinoma of the bladder. Of the 15 evaluable patients, four (26%) achieved a complete response. Systemic and local tolerability were excellent.
UR - http://hdl.handle.net/10447/356860
M3 - Article
VL - 2
SP - 100
EP - 103
JO - International Journal of Urology
JF - International Journal of Urology
SN - 0919-8172
ER -